No Data
No Data
Increasing Losses Over Three Years Doesn't Faze NeoGenomics (NASDAQ:NEO) Investors as Stock Rises 5.3% This Past Week
If you love investing in stocks you're bound to buy some losers. But the last three years have been particularly tough on longer term NeoGenomics, Inc. (NASDAQ:NEO) shareholders. Unfortunately, they
NeoGenomics Earnings Analysis: Q1 Recap
The Q1 earnings report for NeoGenomics (NASDAQ:NEO) was released on Tuesday, April 30, 2024 at 07:30 AM.Here's what investors need to know about the latest announcement.EarningsNeoGenomics beat estima
Piper Sandler Gives a Buy Rating to NeoGenomics (NEO)
NeoGenomics Is Maintained at Buy by BTIG
NeoGenomics Is Maintained at Buy by BTIG
BTIG Maintains Buy on NeoGenomics, Lowers Price Target to $21
BTIG analyst Mark Massaro maintains NeoGenomics (NASDAQ:NEO) with a Buy and lowers the price target from $23 to $21.
Analysts Offer Insights on Healthcare Companies: NeoGenomics (NEO) and Envista Holdings (NVST)
No Data